[1]
Umland EM. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm 2008; 14: 14-9.
[2]
Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population based cohort of women. J Clin Endocrinol Metab 1999; 84: 4025-30.
[3]
Harlow SD, Gass MD, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause 2012; 19(4): 387-95.
[4]
Vliet EL. Menopause and perimenopause: the role of ovarian hormones in common neuroendocrine syndromes in primary care. Prim Care 2002; 29: 43-67.
[5]
Shaver JL, Paulsen VM. Sleep, psychological distress, and somatic symptoms in perimenopausal women. Fam Pract Res J 1993; 13: 373-84.
[6]
Biglia AN, Cagnacci AM, Gambacciani MS, et al. Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric 2017; 1-7.
[7]
Herbison AE. Estrogen regulation of GABA transmission in rat preoptic area. Brain Res Bull 1997; 4: 321-6.
[8]
Hart EC, Charkoudian N, Miller VM. Sex, hormones and neuroeffector mechanisms. Acta Physiol 2011; 203(1): 155-65.
[9]
Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol 1999; 181(1): 66-70.
[10]
Deecher DC. Thermoregulation and menopause: Understanding the
basic pathophysiology of vasomotor Symptoms. Interface between
Gynecology and Psychiatry 2009; 175: 77-87.
[11]
Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990; 592: 52-86.
[12]
Rossouw JE1, Anderson GL, Prentice RL, et al. Women’s Health Initiative (WHI). Risk and benefits of estrogen plus progesterone in healthy post menopausal women. AMA 2002; 288(3): 321-33.
[13]
Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 2003; 289: 3243-53.
[14]
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
[15]
Nelson HD. Menopause. Lancet 2008; 371: 760-70.
[16]
Kober M. Guidance for Industry Estrogen and Estrogen/Progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms—Recommendations for clinical evaluation Food and Drug Administration Center for Drug Evaluation and Research. CDER 2003.
[17]
Freedman RR, Subramanian M. Effects of symptomatic status and the menstrual cycle on hot flash-related thermoregulatory parameters. Menopause 2005; 12: 156-9.
[18]
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over menopause transition. AMA Intern Med 2015; 175(4): 531-9.
[19]
Deecher DC. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin Investig Drugs 2005; 14: 435-48.
[20]
Sievert LL, Morrison L, Brown DE, Reza AM. Vasomotor symptoms among Japanese-American and European-American women living in Hilo, Hawaii. Menopause 2007; 14(2): 261-9.
[21]
Huang AJ, Grady D, Jacoby VL, et al. Persistent hot flashes in older postmenopausal women. Arch Intern Med 2008; 168(8): 840-6.
[22]
Alexander C, Cochran CJ, Gallicchio L, et al. Serum leptin levels, hormone levels, and hot flashes in midlife women. Fertil Steril 2010; 94(3): 1037-43.
[23]
Elavsky S, McAuley E. Personality, menopausal symptoms, and physical activity outcomes in middle-aged women. Pers Individ Dif 2009; 46(2): 123-8.
[24]
Opas EE, Gentile MA, Kimmel DB, et al. Estrogenic control of thermoregulation in ERalphaKO and ERbetaKO mice. Maturitas 2006; 53: 210-621.
[25]
Crawshaw L, Grahn D, Wollmuth L, Simpson L. Central nervous regulation of body temperature in vertebrates: Comparative aspects. Pharmacol Ther 1985; 30(1): 19-30.
[26]
Morrison SF, Nakamura K. Central neural pathways for thermoregulation. Front Biosci 2011; 16: 74-104.
[27]
Stephenson LA, Kolka MA. Esophageal temperature threshold for sweating decreases before ovulation in premenopausal women. J Appl Physiol 1999; 86(1): 22-8.
[28]
Hui Z, Xiaoyan M, Mukun Y, et al. Effects of black cohosh and estrogen on the hypothalamic nuclei of ovariectomized rats at different temperatures. J Ethnopharmacol 2012; 142(3): 769-75.
[29]
Kallo I, Liposits Z, Flerko B, Coen CW. Immunocytochemical characterization of afferents to estrogen receptor-containing neurons in the medial preoptic area of the rat. Neuroscience 1992; 50: 299-308.
[30]
Charkoudian N, Stachenfeld N. Sex hormone effects on autonomic mechanisms of thermoregulation in humans. Auton Neurosci 2016; 196: 75-80.
[31]
Low DA, Hubing KA, Del Coso J, Crandall CG. Mechanisms of cutaneous vasodilation during the postmenopausal hot flash. Menopause 2011; 18(4): 359-65.
[32]
Duckles SP, Miller VM. Hormonal modulation of endothelial NO production. Pflugers Arch 2011; 459(6): 841-51.
[33]
Orshal JM, Khalil RA. Gender, sex hormones and vascular tone. Am J Physiol Regul Integr Comp Physiol 2004; 286(2): 233-49.
[34]
Charkoudian N. Skin blood flow in adult human thermoregulation: How it works, when it does not, and why. Mayo Clin Proc 2003; 78: 603-12.
[35]
Hosono T, Chen XM, Miyatsuji A, et al. Effects of estrogen on thermoregulatory tail vasomotion and heat-escape behavior in freely moving female rats. Am J Physiol Regul Integr Comp Physiol 2001; 280(5): R1341-7.
[36]
Abdelmawla AH, Langley RW, Szabadi E, Bradshaw CM. Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol 1999; 48: 345-54.
[37]
Le Saux M, Di PT. Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: Comparison with tamoxifen and raloxifene. J Psychiatry Neurosci 2005; 30: 110-7.
[38]
Lu NZ, Bethea CL. Ovarian steroid regulation of 5-HT1A receptor binding and G protein activation in female monkeys. Neuropsychopharmacology 2002; 27: 12-4.
[39]
Gundlah C, Pecins-Thompson M, Schutzer WE, Bethea CL. Ovarian steroid effects on serotonin 1A, 2A and 2C receptor mRNA in macaque hypothalamus. Brain Res Mol Brain Res 1999; 63: 325-39.
[40]
Bethea CL, Lu NZ, Gundlah C, Streicher JM. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002; 23: 41-100.
[41]
Gundlah C, Kohama SG, Mirkes SJ, et al. Distribution of estrogen receptor beta (ERbeta) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: Continued expression with hormone replacement. Brain Res Mol Brain Res 2000; 76: 191-204.
[42]
Serova LI, Maharjan S, Huang A, et al. Response of tyrosine hydroxylase and GTP cyclohydrolase I gene expression to estrogen in brain catecholaminergic regions varies with mode of administration. Brain Res 2004; 1015: 1-8.
[43]
Gundlah C, Lu NZ, Bethea CL. Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology (Berl) 2002; 160: 271-82.
[44]
McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002; 57: 357-84.
[45]
Joswig M, Hach-Wunderle V, Ziegler R, Nawroth PP. Postmenopausal hormone replacement therapy and the vascular wall: Mechanisms of 17 beta-estradiols effects’ on vascular biology. Exp Clin Endocrinol Diabetes 1999; 107: 477-87.
[46]
Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor symptoms. J Br Menopause Soc 2006; 12(1): 7-11.
[47]
Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flushes. Fertil Steril 1998; 70: 1-6.
[48]
Cosmi S, Pawlyk AC, Alfinito PD, et al. Simultaneous telemetric monitoring of tail-skin and core body temperature in a rat model of thermoregulatory dysfunction. J Neurosci Methods 2009; 178(2): 270-5.
[49]
Bedell S, Nachtigall M, Naftolin F. The pro and cons of plant estrogens for menopause. J Steroid Biochem Mol Biol 2014; 139: 225-36.
[50]
Oseni T, Patel R, Pyles J, Jordan VC. Selective estrogen receptor modulators and phytoestrogens. Planta Med 2008; 74(13): 1656-65.
[51]
Kostelac D, Rechkemmer G, Briviba K. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J Agric Food Chem 2003; 51: 7632-5.
[52]
Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 139: 4252-63.
[53]
Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000; 141(10): 3657-67.
[54]
Morton MS, Arisaka O, Miyake N, et al. Phytoestrogens concentration in serum Japanese men and women over forty years of age. J Nutr 2002; 132(10): 3168-71.
[55]
Khaodhiar L, Ricciotti HA, Li L, et al. Daidzein-rich isoflavoneaglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008; 15(1): 125-32.
[56]
Bu L, Lephart ED. Effects of dietary phytoestrogens on core body temperature during the estrous cycle and pregnancy. Brain Res Bull 2005; 65(3): 219-23.
[57]
Axelson M, Sjovall J, Gustafsson BE, et al. Soya- a dietary source of the non-steroidal estrogen equol in man and animals. J Endocrinol 1984; 102: 49-56.
[58]
Setchell KD. Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 1998; 68: 1333S-46S.
[59]
Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132(12): 3577-84.
[60]
Howes LG, Howes JB, Knight DC. Isoflavonetheapy for menopausal flushes: A systematic review and meta-analysis. Maturitas 2006; 55: 203-11.
[61]
Messina M, Caan BJ, Abrams DI, et al. It’s time for clinicians to reconsider: their proscription against the use of soy foods by breast cancer patients. Oncology 2013; 430-7.
[62]
Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002; 23: 665-86.
[63]
Si H, Liu D. Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats. J Nutr 2008; 138: 297-304.
[64]
Williamson-Hughes PS, Flickinger BD, Messina MJ, et al. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: A critical review of published studies. Menopause 2009; 13(5): 831-9.
[65]
Han KK, Soares JM Jr, Haidar MA, et al. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002; 99: 389-94.
[66]
Crisafulli A, Marini H, Bitto A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause 2004; 11: 400-4.
[67]
Muthyala RS, Ju YH, Sheng S, et al. Equol, a natural estrogenic metabolite from soy isoflavones: Convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem 2004; 12: 1559-67.
[68]
Akaza H, Miyanaga N, Takashima N, et al. Comparisons of percent equol producers between prostate cancer patients and controls: case controlled studies of isoflavones in Japanese, Korean and American residents. J Clin Oncol 2004; 34: 86-9.
[69]
Fanti P, Sawaya BP, Custer LJ, et al. Serum levels and metabolic clearance of the isoflavones genistein and daidzeinin hemodialysis patients. J Am Soc Nephrol 1999; 10: 864-71.
[70]
Ohkura Y, Obayashi S, Yamada K, et al. S-equol partially restored endothelial nitric oxide production in isoflavone-deficient ovariectomized rats. J Cardiovasc Pharmacol 2015; 65: 500-7.
[71]
Yee S, Burdock GA, Kurata Y, et al. Acute and subchronic toxicity and genotoxicity of SE5-OH, an equol-rich product produced by Lactococcus garvieae. Food Chem Toxicol 2008; 46: 2713-20.
[72]
Yoneda T, Ueno T, Uchiyama S. S-equol and the fermented soy product SE5-OH containing S-equol similarly decrease ovariectomy-induced increase in rat tail skin temperature in an animal model of hot flushes. Menopause 2011; 18(7): 814-20.
[73]
Newton KM, Reed SD, Uchiyama S, et al. A cross-sectional study of equol producer status and self-reported vasomotor symptoms. Menopause 2015; 22(5): 489-95.
[74]
Davinelli S, Scapagnini G, Marzatico V, et al. Influence of equol and resveratrol supplementation on health-related quality of life in menopausal women: A randomized, placebo-controlled study. Maturitas 2017; 77-83.
[75]
Utian W. The role of soy isoflavones in menopausal health: Report of The North American Menopause Society. Translational Science Symposium in Chicago, IL (October 2010). Menopause 2011; 18: 732-53.
[76]
Voloshyna I, Hussaini SM, Reiss AB. Resveratrol in cholesterol metabolism and atherosclerosis. J Med Food 2012; 15(9): 763-73.
[77]
Gehn BD, McAndrews JM, Chien P, et al. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci 1997; 94(25): 14138-43.
[78]
Robb EL, Stuart JA. Resveratrol interacts with estrogen receptor-β to inhibit cell replicative growth and enhance stress resistance by upregulating mitochondrial superoxide dismutase. Free Radic Biol Med 2011; 50(7): 821-31.
[79]
Xia N, Daiber A, Habermeier A, et al. Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein e knockout mice. J Pharmacol Exp Ther 2010; 335(1): 149-54.
[80]
Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biol Pharm Bull 2012; 35(3): 273-9.
[81]
Herbalust RU. American herbal pharmacoporia and therapeutic compendium: black cohosh rhizome. Standards of analysis, quality control and therapeutics. Santa Cruz (CA). AHP 2002; 15: 200-15.
[82]
Margaret R. Alternative treatments for the menopause. Best Practice
& Research Clinical Obstetrics and Gynaecology 2009; 23: 151-61.
[83]
Seidlova-Wuttke D, Hesse O, Jarry H, et al. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17 beta. Eur J Endocrinol 2003; 149(4): 351-62.
[84]
Burdette JE, Liu J, Chen SN, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem 2003; 51(19): 5661-70.
[85]
Lin MT, Tsay HJ, Su WH, Chueh FY. Changes in extracellular serotonin in rat hypothalamus affect thermoregulatory function. Am J Physiol 1998; 274(5 Pt 2): R1260-7.
[86]
Mize AL, Young LJ, Alper RH. Uncoupling of 5-ht1a receptors in the brain by estrogens: Regional variations in antagonism by ici 182,780. Neuropharmacology 2003; 44: 584-91.
[87]
Vitale ML, Chiocchio SR. Serotonin, a neurotransmitter involved in the regulation of luteinizing hormone release. Endocr Rev 1993; 14: 480-93.
[88]
Siddiqui A, Kotecha K, Salicioni AM, et al. Serotonin inhibits luteinizing hormone release via 5-HT1A receptors in the zonaincerta of ovariectomised, anaesthetised rats primed with steroids. Neuroendocrinology 2000; 72: 272-83.
[89]
Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20: 1578-83.
[90]
Duker EM, Kopanski L, Jarry H, Wuttke W. Effects of extracts from Cimicifugaracemosa on gonadotropin release in menopausal women and ovariectomized rats. Planta Med 1991; 57: 420-4.
[91]
Ma X, Zhang H, Wang K, et al. Effects of an isopropanolic-aqueous black cohosh extract on central body temperature of ovariectomized rats. J Ethnopharmacol 2011; 138(1): 156-61.
[92]
Wuttke W. Efficacy and tolerability of the black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study. Maturitas 2006; 55: S83-91.
[93]
Bai W. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: A randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007; 58: 31-41.
[94]
Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. American Journal of Obstetrics
and Gynecology 2008; 11: 455-66.
[95]
Stevens JF, Taylor AW, Deinzer ML. Quantitative analysis of xanthohumol and related prenylflavonoids in hops and beer by liquid chromatography tandem mass spectrometry. J Chromatogr A 1999; 832: 97-107.
[96]
Overk CR, Yao P, Chadwick LR, et al. Comparison of the in vitro estrogenic activities of compounds from hops (Humulus lupulus) and red clover (Trifolium pratense). J Agric Food Chem 2005; 53: 6246-53.
[97]
Roelens F, Heldring N, Dhooge W, et al. Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alpha and beta. J Med Chem 2006; 49: 7357-65.
[98]
Schaefer O, Humpel M, Fritzemeier KH, et al. 8-Prenyl naringenin is a potent ERalpha selective phytoestrogen present in hops and beer. J Steroid Biochem Mol Biol 2003; 84: 359-60.
[99]
Christoffel J, Rimoldi G, Wuttke W. Effects of 8-prenylnaringenin on the hypothalamo-pituitary-uterine axis in rats after 3-month treatment. J Endocrinol 2006; 188(3): 397-405.
[100]
Hümpel M, Isaksson P, Schaefer O, et al. Tissue specificity of 8-prenylnaringenin: protection from ovariectomy induced bone loss with minimal trophic effects on the uterus. J Steroid Biochem Mol Biol 2005; 97(3): 299-305.
[101]
Bowe J, Li XF, Kinsey-Jones J, et al. The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes. J Endocrinol 2006; 191(2): 399-405.
[102]
Rad M, Hümpel M, Schaefer O, et al. Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. Br J Clin Pharmacol 2006; 62: 288-96.
[103]
Heyerick A, Vervarcke S, Depypere H, et al. A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas 2006; 54: 164-75.
Download PDF Flyer